Document registry — page 38
Every document the Institute has published, 1,639 in total, with its identifier, type, certainty rating and review date.
Documents
-
Phase 1 ascending dose, phase 1 study of CJC-1295 in gh axis over multiple weekly doses. Primary result: Cumulative elevation of insulin-like growth factor 1 with…
Low13 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low13 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in obesity over as stated in the parent protocol. The Institute holds no reported…
Very low13 Aug 2023 -
Randomised, double-blind, active-controlled, phase 2 study of CagriSema (cagrilintide with semaglutide) in type 2 diabetes and obesity randomising 92 participants over…
Low12 Aug 2023 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low12 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low11 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Danuglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low10 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Retatrutide in type 2 diabetes randomising 281 participants over 36 weeks. Primary result: Reduction of up…
Moderate09 Aug 2023 -
Phase 1 ascending dose, phase 1 study of Liraglutide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low08 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low08 Aug 2023 -
Observational, phase 3 study of SS-31 (elamipretide) in mitochondrial disease over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low08 Aug 2023 -
Observational, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low07 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 2b study of AOD-9604 in obesity randomising 536 participants over 12 weeks. Primary result: No separation from…
05 Aug 2023 -
Randomised crossover, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 Aug 2023 -
Phase 1 ascending dose, phase 1 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low03 Aug 2023 -
Diagnostic accuracy, phase 3 study of GHRP-2 in gh axis over single test. Primary result: Approved in Japan as a diagnostic stimulation agent. The Institute records that…
Moderate02 Aug 2023 -
Observational, phase 3 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low02 Aug 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low01 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ipamorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary…
Very low01 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 2b study of Danuglipron in obesity randomising 605 participants over 32 weeks. Primary result: Dose-dependent weight…
31 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of Ipamorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary…
Very low30 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity and prediabetes over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low28 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low28 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low27 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result…
Very low27 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low27 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low26 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low26 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Larazotide acetate in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low25 Jul 2023 -
Randomised, open-label, active-controlled, phase 3 study of Exenatide in type 2 diabetes randomising 295 participants over 30 weeks. Primary result: Superior glycaemic…
High24 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Hexarelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low24 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low23 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Hexarelin in lean-mass preservation over as stated in the parent protocol. The Institute holds no reported…
Very low23 Jul 2023 -
Single-arm open-label, phase 1 study of Ipamorelin in gh axis over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low22 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Danuglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low20 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and chronic kidney disease and type 2 diabetes over as stated in the parent…
Very low19 Jul 2023 -
Randomised crossover, phase 1 study of Larazotide acetate in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low19 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low18 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in prediabetes and obesity randomising 2,254 participants over 160 weeks. Primary result…
Moderate17 Jul 2023 -
Randomised crossover, phase 1 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low17 Jul 2023
page 38 of 41